Table 1.
Technical validation.
Test | Conditions tested | Number of
|
Minimal acceptance criteria | Reference |
---|---|---|---|---|
Analyte stability – storage | Samples were stored at -80, 8, and 25°C for up to 14 months. Samples measured at 24 , 48 , 72 h, 8 days, 1, 3, 6, 12, and 24 months |
|
RE% ≤10% from nominal concentration and a weighted deeming slope of 1.0±0 | Guideline on bioanalytical method validation24 |
Analyte stability – freeze-thaw | Samples tested for 3 freeze-thaw cycles |
|
RE% ≤10% from nominal concentration and a weighted deeming slope of 1.0±0 | Guideline on bioanalytical method validation24 |
Reagent stability | Samples tested at 0, 3, 6, 9, 12, and 14 months. Samples stored at -80°C. Timepoint 0 |
|
RE% ≤10% from nominal concentration and a weighted deeming slope of 1.0±0 | CLSI EP2525 and BS EN ISO 23640:201526 |
Interference | Endogenous and exogenous substances were tested at low and high concentrations according to recommendations |
|
RE% ≤10% from nominal concentration | CLSI EP7-A227 |
Precision | Patients samples were used to generate 6 pools of PRO-C3 concentrations covering the measurement range. The study was performed on 2 reagent lots by 2 different operators (operators were swapped between reagent lots every day) along 20 non-consecutive days. |
|
For each sample: CV% ≤10% within 1 run Between-operator reproducibility: for each sample CV% ≤15%. Lot-to-lot variability: for each sample CV% ≤15% between reagent lots. Total precision: For each sample CV% ≤15%. |
CLSI EP05-A328 |
All validations were performed in serum samples from non-alcoholic fatty liver disease patients. CLSI, Clinical and Laboratory Standards Institute; CV%, coefficient of variation; RE%, percent recovery.